Trials in Colorado.
38 APOE4-relevant Alzheimer’s trials run in Colorado — 20 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Carriers enrolled, but higher ARIA riskNCT01767311A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
This Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…
- Built exclusively for APOE 4/4 carriersNCT02565511A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…
- Built specifically for APOE4 carriersNCT03131453A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…
- Open to carriers, but ARIA risk elevatedNCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…
- Enrolled carriers, prior data unfavorableNCT00348309Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
This trial tested whether rosiglitazone extended release, a diabetes drug, could improve thinking and memory in people already taking donepezil for mild to…
- APOE4 stratified, suggests less benefitNCT00428090Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
This Phase 3 trial tested rosiglitazone XR, a diabetes drug already approved for type 2 diabetes, as a standalone treatment for mild to moderate Alzheimer's…
- Open to carriers, not 4-specificNCT02245737An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
This trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, against a placebo over two years in people with early…
- Unrelated to APOE4 or Alzheimer'sNCT02855476HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
HDClarity is collecting cerebrospinal fluid and blood samples from people at various stages of Huntington's disease, plus healthy controls, across multiple…
- Observational only, no treatment involvedNCT02951598A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
This study is not testing a treatment. It is an observational study tracking how people with early-stage Alzheimer's disease or MCI use health care, what that…
- Discontinued trial, not APOE4-specificNCT02972658A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
This Phase 3 trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, in people with early Alzheimer's dementia. It…
- Not APOE4-related, movement disorder focusNCT03924414Trial of Parkinson's And Zoledronic Acid
This trial is testing whether a single IV infusion of zoledronic acid, a bone-strengthening drug already approved for osteoporosis, can reduce fractures in…
- Observational only, genotype not specifiedNCT03944603Longitudinal Innate Immunity and Aging Study
This observational study tracks healthy adults ages 60 to 89 over two years to understand how immune system markers in blood and spinal fluid relate to…
- Open to carriers, not 4-specificNCT04033510Acute Cognitive Changes During Atrial Fibrillation Episodes (AFCOG)
This study tests whether people with atrial fibrillation (an irregular heart rhythm) think and remember less clearly during an AF episode than when their heart…
- Not relevant to APOE4 carriersNCT04165109Trial-Ready Cohort-Down Syndrome (TRC-DS)
This is not a treatment trial. It is a study building a pool of adults with Down syndrome, ages 25 to 55, who are ready to be recruited into future Alzheimer's…
- FTLD-focused, not APOE4-relevantNCT04363684ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
This is a large North American research registry and natural history study tracking people with frontotemporal lobar degeneration (FTLD) and related conditions…
- High ARIA risk for carriersNCT04437511A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it…
- Open to carriers, not 4-specificNCT04902703Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease
This trial is testing sargramostim, an FDA-approved bone marrow drug, to see whether it can slow cognitive decline in people who already have mild-to-moderate…
- Observational only, genotype not specifiedNCT04916210Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
The DISCOVERY study is an observational study — no drug or treatment is being tested. Researchers are following stroke survivors over time, collecting…
- Open to carriers, not 4-specificNCT05399888A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
This Phase 2 trial is testing BIIB080, a drug injected into the spinal fluid, to see whether it can slow cognitive decline in people with mild cognitive…
- Open to carriers, not genotype-specificNCT05421728Effectiveness of Engaging in Advance Care Planning Talks (ENACT) Group Visits in Primary Care for Older Adults With and Without Alzheimer's Disease
This trial tests whether group conversations about advance care planning, led by a geriatrician and social worker in a primary care setting, help older adults…
- Anti-amyloid drug — carriers face higher ARIA riskNCT05463731A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
This Phase 3 trial is testing remternetug, an anti-amyloid antibody given by IV or injection under the skin, in people with early symptomatic Alzheimer's…
- Open to carriers, not 4-specificNCT05479552A Diagnostic Test for Dementia With Lewy Bodies
This study is testing a diagnostic tool called the Syn-One Test, which looks for a protein called alpha-synuclein in a skin biopsy. The goal is to better…
- Open to carriers, not 4-specificNCT05511363A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
This Phase 3 trial is testing KarXT, an oral drug, to see whether it prevents the return of psychosis symptoms — hallucinations and delusions — in people who…
- Not relevant to APOE4 or Alzheimer'sNCT05686551GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
This trial is testing tominersen, a drug injected into the spinal fluid, against a placebo in people with prodromal or early Huntington's Disease. The goal is…
- Late-stage dementia care, not preventionNCT05820919Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
This trial is testing a structured staff-led program called LOCK — focused on light exposure, activity, and consistent routines — to improve sleep in nursing…
- Late-stage AD only, genotype not relevantNCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
This trial is testing whether KarXT, a drug targeting certain brain receptors, is safe to take for up to a year in people who already have Alzheimer's-related…
- Unrelated to APOE4 or Alzheimer'sNCT06667414Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
This study is mapping specific genetic markers called SNPs in people who carry the Huntington's disease gene mutation. Participants give a blood sample and…
- HIV-specific trial, genotype not relevantNCT06705478Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
This Phase 2 trial is comparing two medications — pramipexole (a dopamine-targeting drug used in Parkinson's and restless legs) and escitalopram (a common…
- Open to carriers, not 4-specificNCT06808984Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
This trial tests BMS-986368, an experimental drug that works on the body's endocannabinoid system, to see whether it reduces agitation in people who already…
- Open to carriers, not 4-specificNCT06847321Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
This Phase 2 trial is testing LHP588, an oral capsule taken once daily, in people with mild to moderate Alzheimer's disease who also test positive for P.…
- Open to carriers, not 4-specificNCT06976203A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
MINDSET 2 is testing KarXT plus KarX-EC — a combination drug regimen that works on muscarinic receptors in the brain — to see whether it improves cognition in…
- Open to carriers, not 4-specificNCT06976216A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
This trial is testing KarXT plus KarX-EC, a combination drug approach aimed at improving cognition in people who already have mild to moderate Alzheimer's…
- Open to carriers, not 4-specificNCT07011732A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
This trial is testing two drug combinations — KarXT (xanomeline plus trospium) and KarX-EC — to see whether they reduce agitation in people with confirmed…
- Open to carriers, not 4-specificNCT07011745A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
This trial is testing KarXT plus a new extended-release version called KarX-EC — a non-opioid, non-antipsychotic drug combination — to see whether it reduces…
- Unrelated to APOE4 or Alzheimer'sNCT07326709A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
This trial is testing votoplam, an oral drug designed to slow the progression of early-stage Huntington's disease. Researchers are comparing it against a…
- Not relevant to APOE4 carriersNCT07498426A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
This trial is testing NIO752, an experimental drug, in people diagnosed with Progressive Supranuclear Palsy Richardson Syndrome — a rare and serious brain…
- Observational study, genotype not requiredNCT07563777100-Year Human Aging Study
This is a large, long-term observational study — not a drug or treatment trial. Researchers will screen participants across many health systems and follow them…
- Non-drug option, genotype not a factorNCT07626944Effects of Binaural Beats and Spatialized Music on Behavioural and Psychological Symptoms of Dementia in Assisted Living Facility Residents
This trial is testing whether special types of music listening — binaural beats (subtle audio tones layered into music) and spatialized music (sound engineered…
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.